Clinical Trial Update: A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase II trial update for icotinib in advanced nasopharyngeal carcinoma. The current status of the study is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN